KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $188.0 million.

  • AbbVie's Consolidated Net Income fell 8797.95% to $188.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 5334.11%. This contributed to the annual value of $4.3 billion for FY2024, which is 1204.6% down from last year.
  • As of Q3 2025, AbbVie's Consolidated Net Income stood at $188.0 million, which was down 8797.95% from $941.0 million recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Consolidated Net Income peaked at $4.5 billion during Q1 2022, and registered a low of -$23.0 million during Q4 2024.
  • Its 5-year average for Consolidated Net Income is $1.8 billion, with a median of $1.4 billion in 2024.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 1054473.68% in 2021, then crashed by 10279.13% in 2024.
  • Over the past 5 years, AbbVie's Consolidated Net Income (Quarter) stood at $4.0 billion in 2021, then plummeted by 38.89% to $2.5 billion in 2022, then crashed by 66.67% to $824.0 million in 2023, then crashed by 102.79% to -$23.0 million in 2024, then surged by 917.39% to $188.0 million in 2025.
  • Its Consolidated Net Income stands at $188.0 million for Q3 2025, versus $941.0 million for Q2 2025 and $1.3 billion for Q1 2025.